Merck KGaA
MRK: XETR (DEU)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
€499.00 | Qcktj | Lcmclgzlj |
Merck KGaA Earnings: Healthcare Strength Offsets Weak Life Sciences and Electronics in 2023 Outlook
With help primarily from its biopharmaceutical products in the healthcare segment, narrow-moat Merck KGaA delivered slightly better-than-expected third-quarter results and kept its 2023 outlook intact. Management also reiterated its goal of returning to organic growth in 2024, suggesting that the 2023 declines in its life science and electronics segments will start reversing next year. We are keeping our fair value estimates for the firm (EUR 171/$38) intact, and shares continue to look moderately undervalued.